Botulinum toxin - CKD Bio Corporation
Alternative Names: CKDB-501; CKDB-501A; CKDB-501B; CU-20101Latest Information Update: 28 Jul 2025
At a glance
- Originator CKD Pharmaceuticals
- Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants; Skin disorder therapies; Urologics
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Glabellar lines
- No development reported Muscle spasticity
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Muscle-spasticity in South Korea
- 28 Mar 2025 No recent reports of development identified for phase-I development in Glabellar-lines in South Korea (IM, Powder)
- 11 Jun 2024 Phase-III clinical trials in Glabellar lines in China (Parenteral) (NCT06585696) (CTR20241540)